Coronavirus Drug Discovery

Volume 3: Druggable Targets and In Silico Update

Häftad, Engelska, 2022

Av Chukwuebuka Egbuna, Nigeria) Egbuna, Chukwuebuka (Africa Centre of Excellence in Public Health and Toxicological Research, University of Port Harcourt

2 819 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health.

In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.

Discusses the pathogenic mechanisms of SARS-CoV-2 and druggable targets
Reviews the various signaling pathways associated with SAR-CoV-2 as possible druggable targets
Presents computational approaches and in silico studies against SARS-CoV-2

Produktinformation

Utgivningsdatum2022-07-12
Mått152 x 229 x undefined mm
Vikt630 g
FormatHäftad
SpråkEngelska
SerieDrug Discovery Update
Antal sidor406
FörlagElsevier Science
ISBN9780323955782

Tillhör följande kategorier

Tillverkningsindustri inom Ekonomi och ledarskap
Organisk kemi inom Naturvetenskap och teknik
Farmakologi inom Medicin

Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.

PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS 1. SARS-CoV-2 genome sequencing and promising druggable targets2. Signaling pathways implicated in SARS-CoV2 infection3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of ActionsPART 2: COMPUTATIONAL APPROACHES5. Application of computational tools for coronavirus drug discovery6. In silico Approaches in Drug Discovery for SARS-CoV-27. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins 11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry